Nucleic Acid Pathogen Testing

Medical Coverage Policy Effective Date .. 9/15/2021. Next Review 1/15/2022. Coverage Policy Number .. 0530. Nucleic acid Pathogen Testing Table of Contents Related Coverage Resources Overview .. 1 Preventive Care Services Coverage General Background ..3. Medicare Coverage Determinations ..8. Coding/Billing Information ..9. References ..36. INSTRUCTIONS FOR USE. The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based.

detection. For some pathogens there may be a need to determine the precise concentration of DNA or RNA present, rather than only detecting the presence of the microorganism. This is referred to as nucleic acid quantification. Nucleic acid pathogen testing for chlamydia trachomatis (chlamydia), gardnerella vaginalis, Neisseria gonorrhea ...

Loading..

Tags:

  Pathogens, Testing, Acid, Quantification, Detection, Nucleic, Nucleic acid pathogen testing

Information